Tolmar, Inc., a specialty pharmaceutical company, has officially launched its new Northern Illinois Laboratory at the Innovation and Research Park (IRP) of Rosalind Franklin University in North Chicago, Illinois. This facility will enhance Tolmar’s capacity to develop and commercialize pharmaceutical products, while further enriching the university’s ecosystem of industry innovation.
Founded in 2007, Tolmar is known globally for its advanced long-acting injectable drug delivery systems. The company specializes in the development and manufacturing of injectables in therapeutic areas such as urology, oncology, and endocrinology. Among its flagship products is a treatment for advanced prostate cancer, which is marketed in 89 countries.
Strategic Development and Regional Presence
The new laboratory at Rosalind Franklin University will complement Tolmar’s existing operations in Colorado, where a seasoned team of researchers, engineers, and operations staff is already in place. This expansion not only enhances the company’s research capabilities but also solidifies its regional presence, which includes executive offices and sales personnel based in Buffalo Grove, Illinois.
“Tolmar is excited to expand our development capability, now covering both Colorado and Illinois,” said Dr. Dave Loffredo, Tolmar’s vice president of innovation. “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”
Dr. Stace Porter, senior vice president of development operations for Tolmar, highlighted the advantages of the new facility. “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores. Surrounded by Lake County’s vibrant network of global life science companies, we’re excited to grow and innovate here.”
Collaboration and Innovation Opportunities
The 100,000-square-foot IRP houses six research centers, including the Center for Cancer Cell Biology, Immunology, and Infection. Dr. Joseph DiMario, executive vice president for research at Rosalind Franklin University, expressed enthusiasm for Tolmar’s arrival. “We look forward to collaborations that can help accelerate new product development,” he stated. “The IRP provides an environment that fosters the kind of intellectual biomedical ‘collisions’ that drive meaningful innovation.”
As Tolmar integrates into this innovative space, the collaboration with Rosalind Franklin University promises to yield advancements in pharmaceutical research that could significantly impact patient care across various medical fields.
For more information about Tolmar, please visit www.tolmar.com. To learn more about Rosalind Franklin University, go to rosalindfranklin.edu.
